Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases

[1]  C. Mulder,et al.  Management of Crohn Disease. , 2021, JAMA.

[2]  P. Higgins,et al.  Management of Crohn Disease: A Review. , 2021, JAMA.

[3]  M. Parkes,et al.  Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource , 2020, Gut.

[4]  S. Vermeire,et al.  Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn’s disease , 2020, Gut.

[5]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[6]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[7]  D. D. de Jong,et al.  Real‐life study of safety of thiopurine‐allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment , 2019, Alimentary pharmacology & therapeutics.

[8]  M. Sparrow,et al.  Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  Guanghui Wang,et al.  Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis , 2018, Journal of Crohn's & colitis.

[10]  S. Hanauer,et al.  Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study) , 2018, Alimentary pharmacology & therapeutics.

[11]  C. Mulder,et al.  Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? , 2017, Inflammatory bowel diseases.

[12]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[13]  J. Duley,et al.  Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study , 2016, Inflammatory bowel diseases.

[14]  B. Weiss,et al.  Infliximab-Related Infusion Reactions: Systematic Review , 2015, Journal of Crohn's & colitis.

[15]  A. Ford,et al.  Long-term efficacy and safety of azathioprine in ulcerative colitis. , 2015, Journal of Crohn's & colitis.

[16]  U. Kopylov,et al.  Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[17]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[18]  S. Saxena,et al.  The Role of Thiopurines in Reducing the Need for Surgical Resection in Crohn's Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.

[19]  L. Peyrin-Biroulet,et al.  The Extra Burden of Infliximab Infusions in Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[20]  H. Sokol,et al.  Long-term outcome of patients with Crohn's disease who respond to azathioprine. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  A. V. van Bodegraven,et al.  Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[22]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[23]  M. V. van Oijen,et al.  Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study , 2012, Gut.

[24]  J. Sanderson,et al.  Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. , 2012, Journal of Crohn's & colitis.

[25]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[26]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[27]  Geraint T. Williams,et al.  Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates , 2010, Gut.

[28]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[29]  F. Carrat,et al.  Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study , 2009, Gut.

[30]  M. Schwartz,et al.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[31]  C. J. van der Woude,et al.  Azathioprine treatment during lactation , 2009, Alimentary pharmacology & therapeutics.

[32]  M. Cepoiu,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[33]  J. Dahlerup,et al.  Azathioprine treatment during lactation , 2008, Alimentary pharmacology & therapeutics.

[34]  J. Sanderson,et al.  Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[35]  K. Papadakis,et al.  Hepatotoxicity of 6-Mercaptopurine (6-MP) and Azathioprine (AZA) in Adult IBD Patients , 2007, The American Journal of Gastroenterology.

[36]  V. Armstrong,et al.  6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.

[37]  U. Klotz,et al.  Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.

[38]  U. Klotz,et al.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. , 2007, Clinical pharmacokinetics.

[39]  H Hildebrand,et al.  Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[40]  T. Florin,et al.  Thiopurine Therapies: Problems, Complexities, and Progress With Monitoring Thioguanine Nucleotides , 2005, Therapeutic drug monitoring.

[41]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.